Synapse - William Tap

Results (379)

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib

Journal Article

Desai, J.; Wagner, A. J.; Carrasco Garcia, I.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
Cancer (2025)

Fulltext@MSK | Save

Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

Meeting Abstract

Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

Meeting Abstract

Serrano, C.; Blay, J. Y.; Rutkowski, P.; Gelderblom, H.; Stacchiotti, S.; Falcon Gonzalez, A.; Desai, J.; Le Cesne, A.; Ferraresi, V.; Palmerini, E.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

Meeting Abstract

D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial

Meeting Abstract

Schardt, L. A.; Serrano, C.; Trent, J. C.; Krzeciesa, D.; Newberry, K.; Grassian, A.; Kang, Y. K.; Rutkowski, P.; Jones, R. L.; Heinrich, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)

Meeting Abstract

Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma

Meeting Abstract

Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

Meeting Abstract

Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma

Meeting Abstract

Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Meeting Abstract

Twelves, C. J.; Banerji, U.; Tap, W. D.; Cook, N.; Evans, T. R. J.; Plummer, R.; Anthoney, A.; Plummer, C.; Dawson, R.; Loadman, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

William Douglas Tap

Results (379)

Journal Article

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract